Paysign, Inc. (PAYS)

In the past six months, Paysign, Inc. has experienced significant stock performance and reported strong financial results. On March 24, 2026, Paysign, Inc. announced its fourth quarter and full-year 2025 financial results, reporting full-year 2025 total revenues of $82.0 million, a 40.5% increase from 2024. Net income for full-year 2025 was $7.55 million, up 98% from $3.82 million in 2024. Adjusted EBITDA also saw a substantial rise of 107.3% to $19.94 million. The patient affordability segment was a key driver of growth, with a 167.8% increase in pharma revenue and 55 net new programs added in 2025, bringing the total to 131 active programs. The company's plasma center count increased by 115 during 2025, reaching 595 centers, which contributed to a 4.0% increase in plasma revenue. Between April 7, 2025, and April 2, 2026, the share price increased by 198.99%. The company exited 2025 having repurchased 100,000 shares of common stock for $376 thousand.

The provided information does not explicitly state a significant demand seasonality for Paysign, Inc.'s products and services. The company's ability to add new plasma centers and patient affordability programs consistently suggests a relatively stable or growing demand across its core offerings rather than pronounced seasonality.

Paysign, Inc. is a financial technology company based in Henderson, Nevada, specializing in prepaid card programs and integrated payment processing services. The company operates within the Professional & Commercial Services sector, often categorized under Industrials or Technology (Software - Infrastructure). Paysign provides prepaid card programs, patient affordability solutions, digital banking services, and integrated payment processing for businesses, consumers, and government institutions. Its major products and services encompass prepaid card programs, patient affordability offerings, donor compensation solutions, digital banking services, integrated payment processing, and software solutions. Paysign manages the entire prepaid card lifecycle, serving various industries, including pharmaceuticals, healthcare, hospitality, retail, and government sectors.

Paysign, Inc. is headquartered in Henderson, Nevada, United States. The company's primary market is the United States, with approximately 95% of its revenue generated outside of Nevada.

Paysign, Inc. generally maintains a positive brand reputation as an experienced and trusted prepaid debit card payment solutions provider. Paysign's patient affordability platform is highlighted for its dynamic business rules technology, which has saved clients hundreds of millions of dollars. The company's ownership of its processing switch and payment infrastructure, along with offering open book pricing to pharma clients, has provided a competitive advantage. Paysign's consistent revenue growth and strategic positioning in the fintech-healthcare niche contribute positively to its reputation. The acquisition of Gamma Innovation in March 2025 is seen as a move to deepen relationships with plasma centers and pharmaceutical clients.

Paysign, Inc.'s ownership structure is a mix of institutional, insider, and retail investors. Institutional investors hold a significant portion of the company's stock, ranging from approximately 22.91% to 46.3%. Insiders own approximately 28.46% to 48.77% of the company's stock, with Mark Newcomer, the co-founder and CEO, owning the most shares. Public companies and individual investors hold approximately 5.70% to 36.22% of the stock.